MY Publications

Publications         Google scholar

Published peer review

1. Jonasch E, Atkins MB, Chowdhury S, Mainwaring P. Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the WholeGreater Than the Sum of Its Parts? Cancers (Basel). 2022 Jan 27;14(3):644. doi:10.3390/cancers14030644. PMID: 35158916; PMCID: PMC8833428.
2. Junrong Li, Alain Wuethrich, Abu AI Sina, Han-Hao Cheng, Yuling Wang, Andreas Behren, Paul N Mainwaring, Matt Trau; A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy. Nature communications, 2021; 12; 1; 1-12
3. Chowdhury S, Mainwaring P, Zhang L, Mundle S, Pollozi E, Gray A, Wildgust M. Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. Front Oncol. 2020 Aug14;10:1349. doi: 10.3389/fonc.2020.01349. PMID: 32923387; PMCID: PMC7456898.
4. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021 Jan;79(1):150-158. doi: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6. PMID: 32907777.
5. Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A,
6. Smith MR. Apalutamide and overall survival in non-metastatic castration resistant prostate cancer. Ann Oncol. 2019 Nov 1;30(11):1813-1820. doi: 10.1093/annonc/mdz397. PMID: 31560066; PMCID: PMC6927320.
7. Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10. PMID: 30213449.
8. Young R, Mainwaring P, Clingan P, Parnis FX, Asghari G, Beale P, Aly A, Botteman M, Romano A, Ferrara S, Margunato-Debay S, Harris M. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia Pac J Clin Oncol. 2018 Oct;14(5):e325-e331. doi: 10.1111/ajco.12999. Epub 2018 Jun 22. PMID: 29932294.
9. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.SPARTAN Investigators. N Engl J Med. 2018 Apr 12;378(15):1408-1418
10. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group Mainwaring PN. Lancet Oncol. 2017 Dec;18(12):1688-1700.
11. Detection of aberrant protein phosphorylation in cancer using direct gold-protein affinity interactions. Ahmed M, Carrascosa LG, Ibn Sina AA, Zarate EM, Korbie D, Ru KL, Shiddiky MJA, Mainwaring P, Trau M. Biosens Bioelectron. 2017 May 15;91:8-14
12. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). M. Schmidinger, R.J. Motzer, T. Powles, B. Escudier, N.M. Tannir, N. Mainwaring, B.I. Rini, H.J. Hammers, F. Donscov, B. Roth, K. Peltola, J.L. Lee, D.Y.C. Heng, D.T. Aftab, C. Hessel, C. Scheffold, G. Schwab, S. Pal, T.E. Hutson, T.K. Choueiri Eur J Cancer February 2017 Volume 72, Supplement 1, Pages S187–S188.
13. Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine. Koo KM, Wee EJ, Mainwaring PN, Wang Y, Trau M. Small. 2016 Dec;12(45):6233-6242
14. Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer. Gardiner RA, Mainwaring P, Lavin MF. Eur Urol. 2016 Nov;70(5):749-750
15. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. Harrison SJ, Mainwaring P, Price T, Millward MJ, Padrik P, Underhill CR, Cannell PK, Reich SD, Trikha M, Spencer A. Clin Cancer Res. 2016 Sep 15;22(18):4559-66
16. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. J Clin Oncol. 2016 Sep 1;34(25):3005-13
17. A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA. Koo KM, Wee EJ, Mainwaring PN, Trau M. Sci Rep. 2016 Jul 29;6:30722. doi: 10.1038/srep30722
18. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators.. Lancet Oncol. 2016 Jul;17(7):917-27. doi: 10.1016/S1470-2045(16)30107-3
19. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006
20. Koo KM, Wee EJ, Mainwaring PN, Wang Y, Trau M. Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.. Small. 2016 Dec;12(45):6233-6242. doi: 10.1002/smll.201602161
21. Kevin Koo, Eugene Wee, Paul Mainwaring, Matt Trau. A Simple, Rapid, Low-Cost Technique for Naked-Eye Detection of Urine-Isolate TMPRSS2: ERG Gene Fusion RNA. [Paper #SREP-15-35874A]. Nature Scientfic Reports. July 2016
22. Peter Schmid, Sarah E. Pinder, Duncan WheatleyJane Macaskill, Charles Zammit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwan Hadad, Alice Shia, Shah-Jalal Sarker, Louse Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Mark R. Lackner, Mika Derynck, Timothy R. Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alistair Thompson. Phase II Randomised Preoperative Window-of –Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone In Patients With Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology. Volume 34, Number 17, June 10, 2016. Published online ahead of print at jco.org on March 14, 2016. Doi:10.1200/JCO.2015.63.9179
23. Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae Lyun Lee, Daniel Y. C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N.Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Giseal Schwab, Thomas E. Hutson, Sumanta Pal, Robert J. Motzer, for the METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results From A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology-D-16-00374. http://dx.doi.org/10.1016/ S1470-2045(16)30107-3. Embargo: June 5, 2016-16:12 (BST)
24. Robert A Gardiner, Paul Mainwaring, Martin E Lavin. Integrating Molecular Profiling of Liquid Biopsy Samples With A Calculator Algorithm To Detect High-Risk Prostate Cancer. European Urology. (European Association of Urology). http://dx.doi.org/10.1016/j.eururo.2016.05.12
25. Simon J. Harrison, Paul Mainwaring, Timothy Price, Michael J. Millward, Peeter Padrik, Craig R. Underhill, Paul K. Cannell, Steven D. Reich, Mohit Trikha, Andrew Spencer. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052 Final Results. Manuscript Published Online April 26, 2016; DOI: 10.1158/1078-0432. Clinical Cancer Research-15-2616
26. Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta Pal, Robert J. Motzer for the MMETEOR Investigators. Overall Survival Results from a Randomised Phase 3 Trial Comparing Cabozantinib and Everolimus in Advanced Renal Cell Carcinoma. 11 April 2016. The Lancet Oncology
27. Schuler, J.C.-H. Yank, K. Park, J.H. Kim, J. Bennouna, Y.-M. Cheng, C. Chouaid, F. De Marinis, J.-F. Feng, F. Grossi, D.-W. Kim. X. Liu, S. Lu, J. Strausz, Y. Vinnyk, R. Wiewrodt, C. Zhou, B. Wang, V.K. Chand, D. Planchard for the LUX Lung 5 Investigators. Afatinib Beyond Progression in Patients With Non-Small-Cell Lung Cancer Following Chemotherapy, Erlotinib/Gefitinib and Afatinib: Phase III Randomized LUX-Lung 5 Trial. Annals of Oncology 27: 417-423, 2016. doi:10.1093/annonc/mdv597. Published online 8 December 2015
28. G. Chiorean, D.D. Von Hoff, M. Reni, F.P. Arena, J.R. Infante, V.G. Bathini, T.E. Wood, P.N. Mainwaring, R.T. Muldoon, P.R. Clingan, V. Kunzmann, R.K. Ramanathan, J. Tabernero, D. Goldstein, D. McGovern, B. Lu, A. Ko. CA19-9 Decrease at 8 Weeks as a Predictor of Overall Survival in a Randomized Phase III Trial (MPACT) of Weekly Nab-Palitaxel Plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer. Annals of Oncology Advance Access published January 22, 2016 and March 2, 2016. Annals of Oncology 00: 1-7, 2016. Doi:10. 1093/annonc/mdw006

 

29. Smith MR, de Bono JS, Sternberg CN, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman AM, Holzer W, De Wit R, Bogemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houede N, Hussain Syed, Lamb E, Polikoff J, Stenzi A, Mainwaring P, Ramies DA, Hessel C, Weitzman AL, Fizaz K. Phase 3 Study of Cabozantinib in Previously Treated Metastatic Castration-Resistnt Prostate Cancer (COMET-1). Last Modified 27 Aug. 2015 Journal of Clinical Oncology

 

30. Saad F., Shore N., Van Poppel H., Rathkopf D.E., Smith M.R., de Bono J.S., Logothetis C.J., de Souza P., Fizazi K., Mulders P.F., Mainwaring P., Hainsworth J.D., Beer T.M., North S., Fradet Y., Griffin T.A., De Porre P., Londhe A., Kheoh T., Small E.J., Scher H.I., Molina A., Ryan C.J. Impact of Bone-Targeted Therapies in Chemotherapy-Naïve Metastatic Castration-Resistance Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.32. Epub 2015 May 1

 

31. Paul Mainwaring. Use of Biomarkers in CRPC and Future Treatment in Asia. Prostate Int. 3 (2015) S26-S27. Available Online 22 October 2015. http://dx.doi.org/10.1016/j.prnil.2015.10.001. P2287-8882 e2287-903X

 

32. Paul Mainwaring, Hideyuki Akaza. Emerging Perspectives in Prostate Cancer: Insights from the 4^th Asia Pacific Prostate Cancer Conference. Prostate Int. 3 (2015) S1-S4. Available online 22 October 2015. http://dx.doi.org/10.1016/j.prnil.2015.10.1014. P2287-8882 e2287-903X/Copyright © 2015 Asian Pacific Prostate Society. Published by Elsevier. All rights reserved.

 

33. Paul Mainwaring, Centre for Personalized Nanomedicine, University of Queensland, Australia. The Molecular Pathology of Castrate Resistance Prostate Cancer (CRPC). Prostate Int. 3 (2015) S5-S6. Available Online 22 October 2015. http://dx.doi.org/10.1016/j.prnil.2015.10.013. P2287-8882 e2287-903X

 

34. Peter Schmid, Sarah E. Pinder, Duncan Wheatley, Jane Macaskill, Charles Zummit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwn Hadad, Alice Shia, Shah-Jalal Sarker, Louise Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Marke Lackner, Mika Derynck, Timothy Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alistair Thompson. Phase II Randomized Preoperative Window of Opportunity Study of the P13K Inhibitor Pictilisib plus Anastrozole Compare with Anastrozole Alone in Patients with Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2015.

 

35. Simon J. Harrison, Paul Mainwaring, Timothy Price, Michael J. Millward, Peeter Padrik, Craig R. Underhill, Paul K. Cannell, Francis J. Burrows, Steven D. Reich, Mohit Trikha, Andrew Spencer. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. 2015.

 

36. Gabriela Chiorean, Daniel D. Von Hoff, Michele Bent, Francis P. Arena, Jeffrey R. Infante, Venu G. Bathini, Tina Evans Wood, Paul N. Mainwaring, Robert T. Muldoon, Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Desmond McGovern, Brian Lu, Amy Ko. CA19-9 Decrease at 8 Weeks as Predictor of Overall Survival in a Randomized Phase III Trial (MPACT) of Weekly nab- Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer. Annals of Oncology. 2015.

 

37. Martin E. Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Se-Hoon Lee, John Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul Mainwaring, Robert E. Hawkins, Lucio Crino, Tae Min Kim, Giacomo Carteni, Wilfried Ernst Erich Eberhardt, Ke Zhang, Kolette Fly, Ewa Matcazk, Maria J. Lechuga, Subramanian Hariharan, Ronald Bukowski. Final Results from the Large Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma. British Journal of Cancer. (2015) 113, 12-19 doi: 10.1038/bjc.2015.196

 

38. Fred Saad, Neal Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet,Thomas A. Griffin, Peter De Porre, Anil Londhe, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Impact of Bone-Targeted Therapies in Chemotherapy- Naїve Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. European Urology. 2015.

 

39. Swindle and other authors. A Phase I Clinical Trial of CD1c (BDCA-1) + Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer. Journal of Immunotherapy

 

40. Cora N. Sternberg, Daniel Castellano, Gedske Daugaard, Lajos Géczi, Sebastian J Hotte, Paul N Mainwaring, Fred Saad, Ciro Souza, Miah H Tay, José M Tello Garrido, Luca Galli, Anil Londhe, Peter De Porre, Betty Goon, Emma Lee, Tracy McGowan, Vahid Naini, Mary B Todd, Arturo Molina, Daniel J George. Final Analysis of A Large, Global Early Access Protocol With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. The Lancet Oncology. D-14- 01019R2

 

41. Shaheenah S. Dawood, Xiudong Lei, Rebecca Dent, Paul N. Mainwaring, Bhawn a Sirohi, Rajendra A. Badwe, Sudeep Gupta, Javier Cortes, Ana M. Gonzalez-Angulo. Effect of Age and Tumour Size on Prognostic Outcome of Women with Breast Cancer. J. Clin. Oncol. 32:5s, 2014 (suppl; abstr 592)

 

42. Woo Henry, Begbie Stephen, Gogna Kumar, Mainwaring Paul, Murphy Declan, Parnis Francis, Steer Christopher, Davis Ian. Multidisciplinary Concensus: A Practical Guide for the Integration of Abiraterone Into Clinical Practice. Asia Pacific Journal of Clinical Oncology (APJCO). September 2014. Doi: 10.1111/ajco.12264

 

43. Beer T.M., Armstrong A. J., Rathkopf D. E., Loriot Y., Sternberg C. N., Higano C. S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., Davis I. D., de Bono J. S., Evans C.P., Fizazi K., Joshua A. M., Kim C. S., Kimura G., Mainwaring P., Mansbach H., Miller K., Noonberg S. B., Perabo F., Phung D., Saad F., Scher H. I., Taplin M. E., Venner P. M., Tombal B., PREVAIL Investigators. Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy. N Engl J Med. 2014 Jul 31:371(5):424-33. Doi: 10.1056/NEJMoa1405095. Epub 2014 Jun1. PMIDL24881730

 

44. Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celectia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung-Soo Kim, Go Kimura, Paul Mainwaring, Harry Mansbach, Kurt Miller, Sarah B. Noonber, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary-Ellen Taplin, Peter M. Venner, Bertrand Tombal for the PREVAIL Investigators. Benefit of Enzalutamide in Chemotherapy-Naїve Metastatic Prostate Cancer. New England Journal of Medicine. June 2014

 

45. Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul Mainwaring, Michael Green, Prudence Francis, Richard de Boer, Maree Colosimo, Sue Chua, Jacquie Chirgwin, Jane Beith, Richard Bell. System Treatment of HER2-Positive Metastatic Breast Cancer: A Systemic Review. Asia Pacific Journal of Clinical Oncology 2014; (Suppl. 4): 1-14. Doi:10.1111/ajco.12206. http://onlinelibrary.wiley.com/doi/10.1111/ajco.2014.10.issue-s4/issuetoc

 

46. Paul Mainwaring. Striking the Right Balance for Patients and Innovators: Implications of Association of the Molecular Pathology versus Myriad Genetics Decision. Current Breast Cancer Reports. March 2014, Volume 6, Issue 1, pp 1-2

 

47. Lee SH, Bang YH, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman, Lowenthal S, Chung HC. Sunitinib in Metastatic Renal Cell Carcinoma: An Ethnic Asian Subpopulation Analysis for Safety and Efficacy. Asian Pacific Journal of Clinical Oncology 2014 Sept; 10(3):237-45. Doi: 10.1111/ahco. 12163. Epub 2014 Feb 27. PMID: 24576311

 

48. Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang, Cora N. Sternberg, Cezary Szczylik, Jakub Zolnierek, Christian Kollmannsberger, Sun Young Rha, Georg A. Bjarnason, Bohuslav Meichar, Ugo De Giorgi, Viktor Grünwald, Ian D. Davis, Jae-Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael M. Shi, Bernard Escudier for GOLD Trial investigators. Dovitinib versus Sorafenib for Third-Line Targeted Treatment of Patients with Metastatic Renal Cell Carcinoma: An Open-Label, Randomised Phase 3 Trial. Lancet Oncology 2014. Published Online February 17, 2014. http://dx.doi.org/10.1016/S1470-2045(14)70030-0

 

49. Dana Rathkopf, Matthew R. Smith, Johann S. de Boer, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles,Tom Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia Higano, Mary-Ellen Taplin, Tom Griffin, Mary Todd, Margaret Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad. Updated Interim Efficacy Analysis, and Long-Term Safety of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Association of Urology. http://dx.doi.org/10.1016/j.eururo.2014.02.056

 

50. Dana Rathkopf, Matthew R. Smith, Johann S. de Boer, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles,Tom Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia Higano, Mary-Ellen Taplin, Tom Griffin, Mary Todd, Margaret Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad. Updated Interim Analysis, and Long-Term Safety of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Journal of Urology.

 

51. Fotopoulou C, Vergote I, Mainwaring P, Bidzinksi M, Vermorken JB, Ghamande SA, Harnett P, Del Prete SA, Green JA, Spaczynski M, Blagden S, Gore M, Ledermann J, Kaye S, Gabra H. Weekly AUC2 Carboplatin in Acquired Platinum Resistant Ovarian Cancer With or Without Oral Phenoxodiol, A Sensitizer of Platinum Cytotoxicity: The Phase III OVERTURE Multicentre Randomized Study. Ann Oncol. 2014 Jan;25(1): 160-5. doi: 10.1093/annonc/mdt515. Epub 2013 Dec. 5

 

52. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyeres ML, Molina A, Cleeland C. Abiraterone Acetate plus Prednisone versus Prednisone Alone In Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer: Patient-Reported Outcome Results of a Randomised Phase 3 Trial. Lancet Oncol. 2013 Nov;14(12):11939-9. doi: 10.1016/S1470-2045(13)70424-8. Epub 2013 Sep 25. PMID: 24075621 [PubMed – indexed for MEDLINE]

 

53. John C. Arauja, Gérlyn C. TRudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio V. Serrano, Vsevolod B. Matveev, Eleni Efstathiou, Stephane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goevell, Axel Heidenreich, Johann S. de Bono, Stephen Begbie, Jun H. Hong, Edvardo Richardet, Enrique Gollardo, Prashni Paliwal, Susan Durham, Shinta Cheng, Christopher J. Logothetis. Docetaxel and Dasatinib or Placebo in Men with Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised Double-Blind Phase 3 Trial. The Lancet Oncology. Published Online November 8, 2013. http://dx.doi.org/10.1016/S1470-2045(13)70479-0

 

54. Se-Hoon Lee, Yung-Jue Bank, Paul Mainwaring, Christina Ng, John W-C Chang, Philip Kwong, Rubi K. Li, Virote Sriuranpong, Chee-Keong Toh, Jinua Yuan, Susan Pitman Lowenthal, Hyun C. Chung. Sunitinib in Metastatic Renal Cell Carcinoma: An Ethical Asian Subpopulation Analysis for Safety and Efficacy. Asia Pacific Journal of Clinical Oncology – 2013-0230

 

55. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Olandi F, Gravis G, Matveev, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; on behalf of the VENICE investigators. Aflibercept versus Placebo in Combination with Docetaxel and Prednisone for Treatment of Men with Metastatic Castration-Resistant Prostate Cancer (VENICE): A Phase 3, Double-Blind Randomised Trial. Lancet Oncol. 2013 Jun 3. Pii: S1470-2045(13)70184-0. Doi: 1016/S1470-2045(13)70184-0

 

56. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ: RECORD-1 Trial Study Group. Survival Prediction in /Everolimus-Treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. Eur Urol. 2013 Dec;64(6):994-1002. doi: 1016/j.eururo.2012.11.032. Epub 2012 Nov 21. PMID:23219086 [PubMed – in process]

 

57. Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, Rothman M, Gagnon DD, Kheoh T, Haqq CM, Cleeland C, de Bono JS, Scher HI. Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic Castration-Resistant Prostate Cancer After Docetaxel Chemotherapy. Ann Oncol. 2013 Apr;24(4): 1017-25. doi: 10.1093/annonc/mdd585. Epub 2012 Nov 14. PMID: 23152362 [PubMed – indexed for MEDLINE]

 

58. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ,de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquisst E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584. PMID: 23228172 [PubMed – indexed for MEDLINE]

 

59. Ethan Basch, Karen Autio, Charles J. Ryan, Peter Mulders, Neal Shore, Thian Kheoh, Karim Fizazi, Christophners J. Logothetis, Dana Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles Cleeland. Effect of Abiraterone Acetate on Patient-Reported Pain and Functional Status in Chemotherapy-Naїve Patients With Progressive, Metastatic Castration-Resistant Prostate Cancer. The Lancet Oncology.

 

60. Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng, Joan Carles, Peter F. A Mulders, Ethan Basch, Eric J Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D Mukherjee, Henrik Suttmann, Winald R Gerritsem Thomas W Flaig, Daniel J George, Evan Y Yu, Eleni Efstathiou, Allan Pantuck, Eric Winquist, Celestia S Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas Griffin, Howard I Scher, Dana E Rathkopf, for the COU-AA-302 Investigators. Abiraterone In Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, Dec. 10, 2012. DOI:10 1056/NEJMoa1209096

 

61. Christopher J Logothetis, Ehtan Basch, Arturo Molina, Karim Fizazi, Scott A North, Kim N Chi, Robert J Jones, Oscar B Goodman, Paul N Mainwaring, Cora N Stermberg, Eleni Efstathiou, Dennis D Gagnon, Margaret Rothman, Yanni Hao, Cameron S Liu, Thian S Kheoh, Christopher M Haqq, Howard I Scher, Johann S de Bono. Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data From the COU-AA-301 Randomised Trial. The Lancet Oncol.2012;13:1210-17. Pub. Online November 9, 2012. http://dx.doi.org/10.1016/S1470-2045(12)70473-4

 

62. N. Sternberg, A.Molina, S. North, P. Mainwairng, K. Fizazi, Y. Hao, M. Rothman, D.D. Gagnon, T. Kheoh, C.M. Haqq, C. Cleeland, J.S. de Bono, H.I. Scher. Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic Castration-Resistant Prostate Cancer After Docetaxel Chemotherapy. Annals of Oncology 00: 1-9, 2012. doi:10. 1093/annonc/mds585

 

63. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Cediranib with mFOLFOX6 versus Bevacizumab with mFOLFOX6 as First-Line Treatment for Patients with Advanced Colorectal Cancer: A Double-Blind, Randomised Phase III Study (HORIZON III). J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10. PMID: 22965961 [PubMed – indexed for MEDLINE]

 

64. Karim Fizazi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Kim N. Chi, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stphen Harland, Oscar B. Goodman, Cora N. Sternberg, Jin Hui Li, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono. Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. The Lancet Oncology. Volume 13, Issue 10. Pages 983-992, October 2012. Doi:10.1016/S1470-2045(12)70379-0 (Genitourinary Cancer) Published Online 18 September 2012.

 

65. Howard I. Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N. Chi, Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul Mainwaring, Mark Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono for the AFFIRM Investigators. Increased Survival With Enzalutamide in Prostate Cancer After Chemotherapy. N Engl Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15. PMID: 22894553 [PubMed – indexed for MEDLINE]

 

66. Hendrik Van Poppel, Dana Rathkopf, Matthew R Smith, Johann S de Bono, Chrisopher Logothetis, Neal D Shore, Paul de Souza, Karim Fizazi, Peter FA Mulders, Paul Mainwaring, John D Hainsworth, Tomasz M Beer, Scott North, Yves Fradet, Tom Griffin, Youn C Park, Thian Kheoh, Eric J Small, Howard I Scher, Arturo Molina, Charles J Ryan, on behalf of the COU-AA-302 investigators. Updated Interim Analysis (IA): Results of Randomized Phase 3 Study COU-AA-302 of Abiraterone Acetate (AA) in Metastatic Castration-Resistant Prostate Cancer: The Lancet Oncology 2012; 13:983-92.

 

67. Richard H. de Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Arlene Chan, Rebeca Melara, Yining Ye, Adeboye H. Adewoye, Robert Sikorski, Peter A. Kaufman. Phase 1b Dose-Finding Study of Motesanib with Docetaxel or Paclitaxel in Patients with Metastatic Breast Cancer. Breast Cancer Res Treat (2012), 135:241-252. doi: 10.1007/s10549-012-2135-0.

 

68. ME Gore, C Porta, L Crino, R Hawkins, G Bjarnason, S Oudad, SH Lee, TH Kim, J Yuan, K Fly, C Szczylik, P Mainwaring. Updated Safety and Efficacy Results for Sunitinib from a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. ? 2012

 

69. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Drummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patek K, Schadendorf D.; On behalf of the METRIC Study Group. Improved Survival With MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. Epub 2012 Jun 4. PMID:22663011

 

70. Milward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M, Spear MA. Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel. Invest New Drugs. 2012 June;30(3):1065-73. Epub 2011 Feb 16. PMID:21327495

 

71. Christopher J. Logothetis, Ethen M. Basch, Arturo Molina, Karim Fizazi, Scott A. North, Kim N. Chi, Robert J. Jones, Oscar B. Goodman, Paul N. Mainwaring, Cora N. Sternberg, Eleni Efstathiou, Dennis D. Gagnon, Margaret Rothman, Yanni Hao, Cameron S. Liu,  Thian S.  Kheoh, Christopher M. Haqq, Howard I. Scher, Johann S. de Bono.   Effect of Abiraterone Acetate on Pain Control and Skeletal-Related Events in Patients With Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: Results of the COU-AA-301 Study. Submitted to Journal of Clinical Oncology  March 15 2012.

 

72. Kim N. Chi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jnr.  Exploratory analysis of Survival Benefit and Prior Docetaxel (D) Treatment in COU-hui Li, Thian Kheoh, Christopher M. Haqq, Karim Fizazi. Exploratory Analysis of Survival Benefits and Prior Docetaxel Treatment in COU-AA-301, A Phase 3 Study of Abiraterone Acetate Plus Low-Dose Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Citation: J Clin Oncol 30, 2012 (supl 5; abstr 15).  ASCO GU. San Francisco CA. Feb. 2-4 2012.

 

73. Ethan Basch, Johann S. de Bono, Howard I. Scher, Arturo Molina, Cora N. Sternberg, Karim Fizazi, Scott A.Norht, Kim N.Chi, Robert J.Jones, Oscar B. Goodman, Paul N. Mainwaring, Amanda Farr, Margaret Rothman, Yanni Hao, Cameron S. Liu, Thian Kheoh, Chris M. Haqq, Eleni Efstathiou, Christopher Logothetis. Pain Control and Delay in Time to Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate: Long-Term Follow-Up.  Citation:J Clin Oncol 30, 2012 (suppl 5; abstr 183) ASCO GU Poster. San Francisco CA. Feb. 2-4  2012

 

74. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; On behalf of REACT Study Group. An International Expanded-Access Programme of Everolimus: Addressing Safety and Efficacy in Patients with Metastatic Renal Cell Carcinoma Who Progress After Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. Eur J Cancer. 2012 Feb.; 48 (3): 324-32. Epub 2011 Jul 29. PMID:21803569

 

75. Richard H. De Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Arlene Chan, Rebecca Melara, Yining Ye, Adeboye H Adewoye, Robert Sikorski, Peter A. Kaufan. Phase 1b Dose-Finding Study of Motesanib with Docetaxel or Paclitaxel in Patients with Metastatic Breast Cancer. Submitted to CCR January 2012. Final manuscript submission – BCRT February 2012

 

76. -H. Lee, Y.-J. Bang, P. Mainwairng, C. Ng, J. W.-C. Chang, P. Kwong, R. K. Li, V. Sruranpong,, C.-K. nToh, J. Yuan, S. P. Lowenthal, H.C. Chung. Sunitinib in Metastatic Renal Cell Carcinoma: An Ethnic Asian Subpopulation Analysis for Safety and Efficacy. Annals of Oncology.

 

77. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Hörsch D., Winkler R.E., Klimovsky J., Lebwohl D., Jehl V., Wolin E.M., Oberg K., Van Dutsem E., Yao J.C.; RADIANT-2 Study Group. Everolimus plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendorcrine Tumours Associated with Carcinoid Syndrome (RADIANT-2): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet. 2011 Dec 10;378(9808): 2005-12. Epub 2011 Nov. 25.PMID:22119496

 

78. De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B. Jr, Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., Hutson T.E., Chang T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., Ellard S.L., Fléchon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I.: On behalf of COU-AA-301 Investigators. Abiraterone and Increased Survival in Prostate Cancer. N Eng J Med. 2011 May 26;364(21):1995-2005. PMID: 21612468

 

79. Johann S. de Bono (M.D., Ch.B, PhD.), Christopher J., Logothetis (M.D.), Arturo Molina (M.D.), Karim Fizazi (M.D., PhD.), Scott North (M.D.), Kim N, Chi. (M.D.), Robert J. Jones (M.D.), Oscar B. Goodman, Jr. (M.D., PhD.), Fred Saad (M.D.), John N. Staffurth (M.D., Paul Mainwaring (M.D., M.B., B.S.), Stephen Harland (M.D.), Thomas W. Flaig, M.D.), Thomas E. Hutson, (D.O., Pharm D.), Tina Cheng (M.D.), Helen Patterson (M.D.), John D. Hainsworth (M.D.), Charles J . Ryan (M.D.), Cora N. Stemberg (M.D.), Susan L. Ellard (M.D.), Aude Fléchon (M.D., PhD.), Mansoor Saleh (M.D.), Mark Scholz (M.D.), Eleni Efstathiou (M.D., PhD.), Andrea Zivi (M.D.), Diletta Bianchini (M.D.), Yohann Loriot (M.D.), Nicole Chieffo (M.B.A.), Thian Kheoh (PhD.), Christopher M. Haqq (M.D., PhD.), Howard I. Scher (M.D.) for the COU-AA-301 Investigators. Abiraterone and Increased Survival in Metastatic Prostate Cancer. Engl J Med 2011;364:1995-2005/May 26 2011

 

80. Smith I.E., Pierga J.Y., Biganzoli L., Cortés-Funes H., Thomssen C., Pivot X., Fabi A., Xu B., Stroyakovskiy D., Franke F.A., Kaufman B., Mainwaring P., Pienkowski T., De Valk B., Kwong A., González-Trujillo J.L., Koza I., Petrakova K., Pereira D., Pritchard K.I..; On behalf of the ATHENA Study Group. First-Line Bevacizumab plus Taxane-Based Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: Safety and Efficacy in an Open-Label Study in 2,251 Patients. Ann Oncol. 2011 Mar;22(3):595-602. Epub 2010 Sep 5. PMID:20819780

 

81. Javier Cortes, Joyce O’Shaughnessy, David Loesc, Joanne L Blum, Linda T Vahdat, Katarina Petrakova, Philippe Chollet, Alexey Manikas, Veronique Diéras, Thierry Delozier, Vladimir Vladimirov, Fatima Cardoso, Han Koh, Phillipe Bougnous, Corina E.Dutcus, Seth Seegobin, Denis Mir, Nicole Meneses, Jantien Wanders, Chris Twelves: On behalf of the EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice versus E7389) Investigators. Eribulin Monotherapy versus Treatment of Physician’s Choice in Patients With Metastatic Breast Cancer (EMBRACE):A Phase 3 Open-Label Randomised Study. Lancet 2011;377:914-23. Published on-line March 3 2011

 

82. Millward M., Mainwaring P., Mita A., Federico K., Lloyd G.K., Reddinger N., Nawrocki S., Mita M., Spear M.A.. Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel. Invest New Drugs. 2011 Feb 16. PMID:21327495

 

83. Motzer R. J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grünwald V., Thompson J.A., Figlin R.A., Hollaender N., Kay A., Ravaud A.; On behalf of RECORD-1 Study Group. Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors. Cancer. 2010 Sept. 15;116(18):4256-65

 

84. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K.. Mainwaring P.   On behalf of ToGA Trial Investigators. Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase III, Open-Label, Randomized Controlled Trial. Lancet. 2010 Aug. 28;376 (9742): 687-97. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.PubMed PMID: 20728210.

 

85. Hill J, Treasure T.; On behalf of the Guideline Development Group. Reducing the Risk of venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital: Summary of the NICE Guideline. Heart. 2010 June;96(11):879-82. No abstract available. PMID:20478866

 

86. Roberto Pili, Mark Rosenthal, Mainwaring Paul, Guy Van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph Leach, Shirley Wong, Peter Clingan. Phase II Study of the Addition of ASA404 (Vadimezan), 5, 6- dimethylxanthenone-4-acetic acid (DMXAA) to Docetaxel in Castration-Refractory Metastatic Prostate Cancer. Clinical Cancer Research 2010 May 15; 16 (10): 2906-14. Epub 2010 May 11. PubMed PMID: 20460477

 

87. Hill J, Treasure T. On behalf of the National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the Risk of Venous Thromboembolism in Patients Admitted to Hospital: Summary of NICE Guidance. BMJ. 2010 Jan 27;340:c95. doi: 10.1136/bmh.c95. No abstract available. PMID:20106897

 

88. McKeage M. J. Reck M, Jameson M.B., Gibbs D, Rosenthal M, Mainwaring P, Von Pawel J,   Freitag L, Sullivan R.  Phase II Study of ASA404 (Vadimezan, 5, 6-Dimethylxanthenone-4-Acetic Acid/DMXAA 1800mg/m² Combined with Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2009 Aug;65 (2): 192-7. Epub 2009 May 5. Pubmed PMID:19409645

 

89. Alberto Sobrero, Scott Young, Margaret Balcewicz, Silvana Chiarra, Ramon Perez Carrion, Paul Mainwaring, John Gapski, Stephen Clarke, Bernd Langer, Stephen Ackland. AVIRI Trial Investigators. Phase IV study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. Oncology 2009; 77 (3-4):256.Following 119. Chiara, Silvia [corrected to Chiara, Silvana]. PubMed PMID: 19628950

 

90. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrodljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and Efficacy Sunitinib for Metastatic Renal Cell Carcinoma (mRCC): An Expanded Access Trial. Lancet Oncol. 2009 Aug; 10 (8): 757-63. Epub 2009 Jul 15. PubMed PMID: 19615940

 

91. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D.; On behalf of the First BEAT investigators. Safety and Efficacy of First-Line Bevacizumab with Folfox, Xelox, Folfiri and Fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 2009. April 30

 

92. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RT, Tabah-Fisch I, Cassidy J. Two Different First-Line 5-Fluororacil Regimens With or Without Oxaliplatin in Patients with Metastatic Colorectal Cancer. Ann Oncol. 2009 Feb;20(2):244-50. Epub 2008 Oct 14. PMID:18854549

 

93. Tarhini AA, Milward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM. A Phase 2, Randomized Study of SB-485233, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma. Cancer. 2009 Feb 15;115(4):859-68. PMID:19140204

 

94. McKeage MJ, Von Pawl J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PM, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised Phase II Study of ASA404 Combined With Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. Br J Cancer. 2008 Dec 16;99(12):2006-12 PMID:19078952

 

95. Sobrero, S. Ackland, S. Clarke, R. Perez-Carrión, S. Chiara, J. Gapski, P. Mainwaring, B Langer, S. Young (for the AVIRI Trial Investigators. Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFORI) in First-Line Metastatic Colorectal Cancer. August. 2008

 

96. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. On behalf of the RECORD-1 Study Group. Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial. Lancet. 2008 Aug 9;372(9637):449-56. Epub 2008 Jul 22. PMID:18653228

 

97. Ahmad A. Tarhini, Michael Millward, Paul Mainwaring, Richard Kefford, Ted Logan, Anna Pavlick, Steven J.Kathman, Kevin H. Laubscher, Mohammed M. Dar, John M. Kirkwood. A Phase II, Randomized Study of SB-485232, rhIL-18, in Patients with Previously Untreated Metastatic Melanoma. SB-485232006. Cancer. 04-130 IL-18. January 2008

 

98. Mark J. McKeage, Joachim Von Pawel, Michael B. Jameson, Mark Rosenthal, Richard Sullivan, David Gibbs, Paul Mainwaring, Martin Reck, Monique Serke, Jean-Jacques Lafitte, Christos Chouaid, Lutz Freitag, and Elisabeth Quoix.. Randomized Phase Ib/II Study of 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA/ASA404) Combined with Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. Submitted J Clin Oncol

 

99. Vera Hirsh, John Glaspy, Paul Mainwaring, Christian Manegold, Rodryg Ramlau and Joseph E Eid. Phase II Study of Two Dose Schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Anemic Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy. Trials 2007 Mar 6;8:8. PMID:17341293

 

100. Mainwaring PN. Angiogenesis Inhibitors in Cancer – Clinical Applications. Australian Prescriber. 29 (1) 2006.

 

101. Nicholson C, Jackson CL, Wright B, Mainwaring P, Holliday D, Lankowski A and Kardash C. Online Referral and OPD Booking From The GP Desktop – Building Electronic Linkage Between Hospital and Community Providers. Australian Health Review August 2006 Aug;30(3):397-404. PMID:16879099

 

102. Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DN. The Immune Response to Breast Cancer, and the Case for DC Immunotherapy. 2004;6(2):154-63. Review. PMID:15203992

 

103. Mainwaring P, van Cutsem E, Makris, A. A Randomised Study of Oral UFT (Uracil/Tegafur) Plus Leucovorin or Parenteral 5-Fluorouracil plus Leucovorin in Patients With Metastatic Colorectal Cancer. Eur J Cancer 2004

 

104. Van Cutsem E, Mainwaring P, van Laethem J, Husseini F, Twelves C, Propper D, Bridgewater J, Stuart N, Punt C, Carmichael J, Ravic M, Yule SM. A Randomised Phase II Multi-Centre Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent in 5-Fluorouracil Pre-Treated Colorectal Cancer. Ann Oncol submitted

 

105. MainwaringN. Judson I. High Dose Rapid Schedule Treatment with Ifosfamide, Etoposide, Cyclophosphamide and G-CSF For Poor Prognosis Sarcomas. (Accepted subject to revision Sarcoma)

 

106. Mainwaring PN, Cunningham D, Gregory W, Hoskin P, Hancock B, Norton AJ, MacLennan K, Smith P, Hudson GV, Linch D. Mitoxantrone is Superior to Doxorubicin in a Multi-agent Weekly Regimen for Patients Older Than 60 With High-Grade Lymphoma: Results of a BNLI Randomized Trial of PAdriaCEBO versus PMitCEBO. Blood. 2001 May 15;97(10):2991-7.

 

107. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Singhal S, Mehta J. The Role of Autologous Transplantation in Patients with Multiple Myeloma aged 65 Years and Over. Bone Marrow Transplant; 25(5):533-9 2000

 

108. Sumpter K, Powles RL, Raje N, Ramiah V, Kulkarni S, Treleaven J, Mainwaring PN. Oral Idarubicin As A Single-Agent Therapy in Patients With Relapsed or Resistant Multiple Myeloma. Leuk Lymphoma. 1999 Nov;35(5-6):593-7. PMID:10609797

 

109. Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE. Clinical Studies of Apoptosis and Proliferation in Breast Cancer. Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review.

 

110. Dowsett M, Detre S, Ormerod MG, Ellis PA, Mainwaring PN, Titley JC, Smith IE. Analysis and Sorting of Apoptotic Cells from Fine-Needle Aspirates of Excised Human Primary Breast Cancer. Cytometry. 1998 Aug 1;32(4):291-300. PMID 9701398

 

111. Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M. Comparison of In Situ Methods to Assess DNA Cleavage in Apoptotic Cells in Patients with Breast Cancer. J Clin Pathol. 1998 Jan;51(1):34-7. PMID:9577369

 

112. Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE. Continuous Infusional Topotecan in Advanced Breast and Non-Small Cell Lung Cancer: No Evidence of Increased Efficacy. Br J Cancer. 1997;76(12):1636-9. PMID:9413954

 

113. Mainwaring PN, Atkinson H, Chang J, Moore J, Hancock BW, Guillou PJ, Oskam R, Gore ME. Differential Responses to Chemoimmunotherapy in Patients with Metastatic Malignant Melanoma. Eur J Cancer 1997 Aug;33(9):1388-92. PMID:9337679

 

114. Gregory RK, Mainwaring PN, Hill M, Pyle L, Ramsden MA, Gore ME. Can Paclitaxel be Delivered by Continuous Ambulatory Infusion? Br J Cancer 1997 76: Suppl 1: P09.

 

115. Gore, M. E., Mainwaring, P. N., Macfarlane, V., A’Hern, R., Osborne, R., Harper, P., Quigley, M., Slevin, M., Jones, A., Mansi, J. Blake, P. A Randomized Study of High versus Standard Dose Carboplatin in Patients with Advanced Epithelial Ovarian Cancer. J Clin Oncol; 16(7): 2426-34.

 

116. Mainwaring, P.N., Atkinson, H., Chang, J., Moore, J., Hancock, B.W., Guillou, P.J., Oskam, R., Gore, M.E. Differential Responses to Chemoimmunotherapy in Patients with Metastatic Melanoma. Eur J Cancer 1997, Vol.33, No.9, pp.1388-1392

 

117. Mainwaring PN, Gore ME. The Importance of Dose and Schedule in Cancer Chemotherapy: Epithelial Ovarian Cancer. Anticancer Drugs. 1995 Oct;6 Suppl 5:29-41. PMID:8845493

 

118. Mainwaring, P.N., Grygiel, J.J. Interaction of 5-Fluorouracil with Folates. Aust New Zealand J Med 25; 1: 60 1995

 

119. Childs AM, Coates AS, Cox KM, Mainwaring Severe Vascular Adverse Effects with Thrombocytopenia and Renal Failure Following Emetogenic Chemotherapy and Ondansetron. Ann Oncol 1994 Jan;5(1):98. PMID:8172803

 

 

 

Book Chapters

 

1. MainwaringN., Tattersall M.H.N. An Integrated Approach to the Management of Cervix Cancer. Ed. Professor DM Luesley Birmingham Health Authority.

 

2. Smith I.E., Mainwaring, P.N. Primary Medical Therapy for Breast Cancer, Textbook Chapter in The Management of Breast Cancer, G Bonadonna Ed. Martin Dunitz, London 1997

 

3. MainwaringN., Dowsett, M. LHRH Superagonists And Antagonists In The Treatment Of Breast Cancer. Endocrinology Of The Breast – A Manni, Ed. Humana Press Inc, Totowa, New Jersey, U.S.A. 1997

 

4. Mainwaring, P.N. & Timothy, A.R. PET: Diagnosis and Management of Lymphomas in Annual of Lypmhoid Malignancies, Ed Cavalli, F. Matin Dunitz Publishers, London, 2000

 

5. Mainwaring, P.N.. Current and Future Strategies for the Management of Colorectal Cancer. Primary Care in the New NHS, The Journal of Primary Care Groups and Trusts, Autumn 2000.

 

6. Mainwaring, P.N.. Medical Developments the Management of Colorectal Cancer. Primary Care in the New NHS, The Journal of Primary Care Groups and Trusts, Autumn 2001.
7. Osterling, Mainwaring PN Treatment Strategies Targeting Inhibition of Epidermal Growth Factor Receptor Expression in Advanced cancer. Current Medical Literature, October 2002
8. Mainwaring PN. Scientific Evidence and Expert Opinion for Adjuvant Chemotherapy in Colorectal Cancer. Key Advances Series, London 2003

 

9. Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid Phase II Study of Two Dose Schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Anemic Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Receiving Chemotherapy.

MD Thesis

Proliferation, Apoptosis And Control Of Apoptosis In The Endocrine Management Of Human Breast Cancer

 

The University of London

 

 

Published Abstracts

1. Phase 2 Study of Sequential First-line Pazopanib (PAZ) Followed by Everolimus (EVE) in Patients (pts) with Advanced or Metastatic Renal Cell Carcinoma (RCC) (CATChEz Study) Paul de Souza, Shirley Wong, Sanjeev Sewak, Dusan Kotasek, Bhumsuk Keam, Jinsoo Chung, Jackie Han, Luca Dezzani, Qasim Ahmad, Paul Mainwaring 17th International Kidney Cancer Symposium 2018, Miami Florida USA
2. Matthew R. Smith, Carlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, Caly Chien, Hiroji Uemura, David Olmos, Paul Mainwaring, Ji Youl Lee, Margaret Yu, Juan-Jose Perez-Ruixo, Eric J. Small. Relationship Between Apalutamide (APA) Exposure and Metastasis-Free Survival (MFS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN. ESMO 2018
3. USANZ
4. TROG
5. Eric J. Small, Fred Saad, Boris A. Hadaschik, Julie N. Graff, Paul N. Mainwaring, Kelly McQuarrie, Susan Li, Joe Lawson, Angela Lopez-Gitlitz, Matthew R. Smith. Patient reported outcomes in SPARTAN a Phase 3 Double-Blind Randomised Study of Apalutamide plus ADT vs Placebo plus ADT in men with Nonmetastatic Castration-Resistant Prostate Cancer. AUA May 2018
6. Eric Jay Small, Fred Saad, Simon Chowdhury, Boris A. Hadaschik, Julie Nicole Graff, David Olmos, Paul N. Mainwaring, Hiroji Uemura, Angela Lopez-Gitlitz, Geralyn Carol Trudel, Byron M. Espina, Youyi Shu, Youn C. Park, Wayne R. Rackoff, Margaret K. Yu, Matthew Raymond Smith, on behalf of the SPARTAN investigators; SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) vs placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO GU February 2018
7. Paul de Souza, Shirley Wong, Sanjeev Sewak, Dusan Kotasek, Bhumsuk Keam, Jinsoo Chung, Noelle Erbeck, Jackie Han, Luca Dezzani, Qasim Ahmad, Paul Mainwaring

Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study) ASCO GU 2018

 

8. Cella, B. Escudier, N.M Tannir, T. Powles, F. Donskov, K. Peltola, M. Schmidinger, D.Y.C. Heng, P.N. Mainwaring, H. Hammers, J.L Lee, B.I. Rini, B.J. Roth, J. Baer, M. Mangeshkar, C. Scheffold, T.E. Hutson, S. Pal, R.J. Motzer, T.K. Choueiri. Quality of Life (QoL) in the Phase 3 METEOR Trial of Cabozantinib vs Everolimus for Advanced Renal Cell Carcinoma. (RCC). ESMO (European Society for Medical Oncology, Copenhagen (Denmark), 7-11 Oct. 2016

 

9. Toni K. Choueiri, Thomas Powles, Bernard Escudier, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce Roth, Katrina Peltola, Jae Lyun Lee, Daniel Y. C. Heng, Manuela Schmidinger, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Sumanta Pal, Thomas E. Hutson, Robert J. Motzer. Overall Survival (OS) in METEOR, A Randomised Phase 3 Trial of Cabozantinib (Cabo) versus Everolimus (Eve) in Patients (pts) with Advanced Renal Cell Carcinoma (RCC). ASCO (American Society of Clinical Oncology). Chicago June 3 – 7, 2016

 

10. Sartor, S. Oudard, L. Sengeløv, G. Daugaard, F. Saad, S. Hansen, M. Hjelm-Eriksson, J. Jassem, A. Thiery Vuillemin, O. Caffo, D. Castellano, P.N. Mainwaring, J. Bernard, L. Shen, M. Chadjaa, K. Fizazi. Carbazitaxel vs Docetaxel in Chemotherapy-Naïve (CN) Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): a 3-Arm Phase III Study (FIRSTANA). ASCO (American Society of Clinical Oncology). Chicago June 3 – 7, 2016.

 

11. Paul N. Mainwaring, Christopher Pyke, Darren Korbie, Michael Pheasant, Dennis Gascoigne, Ken Musgrave, Kate O’Neill, Kelly McGrath, Mathias Trau. Multi-Platform Quality Assurance (QA) Comparison of Next-Generation Sequencing 9NGS) Technologies Incorporating Novel Simultaneous Mutation and Copy Number Variation (CNV) Reporting. ASCO (American Society of Clinical Oncology). Chicago. May 29 – June 2, 2015.

 

12. Beer T.M., Armstrong A., Sternberg C.N., Higano C.S., Rathkopf D.E., Loriot Y., Saad F., Joshua A.M., De Bono J.S., Venner P., Carles J., Mainwaring P., Evans C.P., Parki T., Mansbach H., Bhattacharya S., Van Os S., Phung D., Tombal B. Enzalutamide (ENZA) in Men with Chemoterapy-Naïve Metastatic Castration-Resistanct Prostate Cancer (mCRPC): Final Analysis of the Phase 3 PREVAIL Study. ASCO (American Society of Clinical Oncology). Chicago. May 29 – June 2, 2015.

 

13. Paul Mainwaring, Glenn Liu, Ji Youl Lee, Andrey Semenov, Sheela Tejwani, Primo Lara, Jr, Géralyn C. Trudel, Antonieta Sosa, Thian Kheoh, Margaret K. Yu, Brenden Rooney, Byron Espina, Matthew R. Smith, Eric J. Small. SPARTAN – A Randomized Double-Blind, Comparative Study of ARN-509 plus Androgen Deprivation Therapy (ADT) vs ADT Along in Non-Metastatic Catrastion-Resistant Prostate Cancer (MO-CRPC). USANZ (Urology Society of Australia and New Zealand) 68^th Annual Scientific Meeting. Adelaide. 11-14 April 2015

 

14. Paul Mainwaring, Noan Minh Chau, Ph-Hui Chiang, Wing Ming Ho, Elizabeth Hovey, Ji Youl Lee, Siobhan Ng, See-Tong Pang, Phillip Parente, Vichien Srimuninnimit, Hui Meng Tan, Miah-Hiang Tay, Anil Londhe, Janis Mae Pagtakhan-Galgana, Max Van Kooten Losio, Arturo Molina. Early Access Protocol with Abiraterone Acetate for Patients in the Asia-Pacific Region with Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. USANZ (Urology Society of Australia and New Zealand) 68^th Annual Scientific Meeting. Adelaide. 11-14 April 2015.

 

15. Ian D. Davis, Choung-Soo Kim, Go Kimura, Weber Lu, Sarah B. Noonberg, Frank Perabo, Suman Bhattacharya, De Phung, Bertrand Tombal, Tomasz M. Beer, N. Mainwaring. Enzalutamide in Men with Chemotherapy-naїve Metastatic Castration Resistant Prostate Cancer (mCRPC): Primary and Australian/Asian Regional Results of the Phase 3 PREVAIL Study. Abstract. World Cancer Congress. Melbourne. December 3-6, 2014.

 

16. Darren Korbie, Michael Pheasant, Paul Mainwaring, Christopher Pyke, Kate O’Neill, Erica Lin, David Wall, Carissa Phillips, Ken Musgrave, Matt Trau. New Paradigms in Clinical Cancer Pathology: Comprehensive Molecular Profiling of Prospective Breast Cancer Samples in 7 Days Using Benchtop Seqencing Platforms. IABCR. (International Association for Breast Cancer Research) 14-17 September 2014. Novotel Sydney Manly Pacific.

 

17. Sardjono, J. Bower, P. McCloud, P. Mainwaring, S. Sewak, S. Wong, D. Kotasek, S.H. Lee, J.S. Chung, J. Sanmugarajah, S. Troon, D. Yip, S. Singh, D. Crump, D. De Souza. A Phase II Study of Sequential Therapy With Pazopanib Followed By  Everolimus in Metastatic Renal Cell Cancer – Study Update. Abstract MOGA (Medical Oncology Group of Australia Incorporated). Sydney 6-8  August 2014.

 

18. Cora N. Sternberg, Gédske Daugaard, Lajos Geczi, Sebastien J. Hotee, Paul N. Mainwaring, Fred Saad, Ciro Souza, Miah T. Tay, José M. Tello Garrido, Luca Galli, Anil Londhe, Peter De Porre, Dan Atlan, Betty Goon, Emma Lee, Tracey McGowan, Vahid Naini, Mary B. Todd, Arturo Molina, Daniel J. George. Final Analysis of a Large, Open-Label Global Early Access Protocol With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. Abstract #5061 General Poster Session: Genitoruinrary (Prostate) Cancer. ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 2, 2014.

 

19. Shaheenah S. Dawood, Xiudong Lei, Rebecca Dent, Paul N. Mainwaring, Bhawn a Sirohi, Rajendra A. Badwe, Sudeep Gupta, Javier Cortes, Ana M. Gonzalez-Angulo. Effect of Age and Tumour Size on Prognostic Outcome of Women with Breast Cancer. ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 2, 2014.

 

20. Paul N. Mainwaring, Christopher Pyke, Darren Korbie, Michael Pheasant, Kate O’Neill, Ken Musgrave, Mattias Trau. Quality Assurance Study of Real-Time Targeted Massive Parallel Sequencing (MPS) Comprehensive Cancer Panel (CCP) and Network Pathway Analysis in Early Breast Cancer (EBC). Abstract ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 3 2014.

 

21. Andrew Armstrong, Bertrand Tombal, Cora N. Sternberg, Celestia Higano, Dana E. Rathkopf, Yohann Loriot, Fred Saad, Anthony M. Joshua, Johann De Bono, Peter Venner, Joan Charles, Paul Mainwaring, Christopher P. Evans, Sarah B. Noonberg, Hank Mansbach, Suman Bhattacharya, Frank Perabo, De Phung, Tomasz B. Beer. Primary, Secondary and Quality of Life, Endpoint Results from PREVAIL, a Phase 3 Study of Enzalutamide in Men with Metastatic Castrate Resistant Prostate Cancer. Abstract. ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 3 2014.

 

22. Neal D. Shore, Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Efficacy and Long-Term Safety Analysis of Study COU-AA-302: Abiraterone Acetate (AA) Plus Prednisone (P) in Chemotherapy- Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC). AUA (American Urological Association) Abstract.16^th – 21^st May 2014. Orlando,Florida, USA.

 

23. A/Prof Christopher Pyke, A/Prof Paul Mainwaring, Matt Trau, Dr Glenn Francis, Dr Darren Korbie, Dr Michael Pheasant. Quality Metric Study of Real-Time Targeted Massive Parallel Sequencing (MPS) (Ampliseq Comprehensiv Cancer Panel (CCP) and Bioinformatics in Early Breast Cancer (EBC) Using Life Technologies Ion Proton System. RACS Annual Scientific Congress. ANZCA Annual Scientific Meeting. Sands Expo and Convention Centre, Marina Bay Sands, Singapore. May 5 – 9 2014.

 

24. Paul Mainwaring, Evan Y. Yu, Fred Saad, Anil Londhe, Neil Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, John D. Hainsworth, Thomasz M. Beer, Scott North, Eric J. Small, Howard I. Scher, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan. Association of Alkaline Phosphatase With Clinical Outcomes in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results From COU-AA-302. Urological Society of Australia and New Zealand (USANZ). 16-19 March 2014. Brisbane. Australia

 

25. Evan Y. Yu, Fred Saad, Anil Londhe, Neil Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D.Hanisworth, Tomasz M. Beer, Scott North, Erica J. Small, Howard I. Scher, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan. Association of Alkaline Phosphatase (ALP) With Clinical Outcomes in Chemotherapy-Naïve Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from COU-AA-302. Abstract #123692. ASCO GU. 30^th January – 1^st February 2014. San Francisco Marriott Marquis, San Francisco

 

26. M. Beer, A. Armstrong, C. Sternberg, C. Higano, P. Iverson, Y. Loriot, D.E. Rathkopf, S. Bhattacharya, J. Carles, J. de Bono, C.P. Evans, A. Joshua, C. Kim, G. Kimura, P. Mainwaring, H. Mansbach, K. Miller, S. Noonber, P. Venner, B. Tombal. Enzalutamide in Patients with Chemotherapy-Naïve Metastatic Prostate Cancer: Results from the Phase 3 PREVAIL Study. Abstract. ASCO GU. 30^th January – 1^st February 2014. San Francisco Marriott Marquis, San Francisco

 

27. Korbie, M. Pheasant, K. O’Neill, P. Mainwaring, M. Trau. Technical Assessment of Multiplex Targeted Resequencing Applications for Somatic Mutation Detection: Amplicon Representation, Reproducibility and Bias of the Ampliseq Comprehensive Cancer Panel and TruSight Tumour Panel Across 250 Patient Samples. San Antonio Breast Cancer Symposium. San Antonio, Texas. 10^th – 14^th December 2013.

 

28. Paul de Souza, Dana Rathkopf, Matthew R Smith, Peter F.A. Mulders, Paul Mainwaring, Scott North, Thomas Griffin, Youn C. Park, Arturo Molina, Charles J. Ryan. Long-Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Study COU-AA-302 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy. Prostate Cancer World Congress 2013. 6-10^th August 2013. Melbourne Convention and Exhibition Centre, Melbourne, Victoria, Australia.

 

29. Michele Reni, Daniel D. Von Hoff, E. Gabriela Chiorean, Thomas Ervin, Francis P. Arena, Jeffrey R. Infante, Venu Bathini, Tina Wood, Paul Mainwaring, Robert Muldoon, Philip Clingan,Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu. CA19-9 Decrease and Kinetics in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel (nab-P) plus Gemcitabine (G) vs G Alone in Patients With Metastatic Pancreatic Cancer (PC). ESMO 15^th World Congress On Gastrointestinal Cancer. 3^rd-6^th July 2013. Barcelona, Spain.

 

30. Gabriela Chiorean, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, Jeffrey R. Infante, Venue Gopal Bathini, Tina Evans Wood, Paul N. Mainwaring, Robert T. Muldoon, Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu. CA19-9 Decrease at 8 Weeks as a Predictor f Overall Survival (OS) in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel (nab-P) plus Gemcitabine (G) vs G Alone in Patients with Metastatic Pancreatic Cancer. Abstract #117231. ASCO (American Society of Clinical Oncology), 31^st May – 4^th June 2013.

 

31. Dana Rathkopf, Matthew R Smith, Johann S de Bono, Christopher Logothetis, Neal D Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Long Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy (COU-AA-302). Abstract #111574. ASCO (American Society of Clinical Oncology), 31^st May – 4^th June 2013.

 

32. Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Daniel Ford, Loic Mourey, Phillip Parente, Shapiro, Igor Latorzeff, Istvan Bodrogi, Choung-Soo Kim, Albert Font, Roanne Segal, Hendrik Pieter Van Den Berg, Wenping (Wendy) Zhang, Mustapha Chadjaa, Johann Sebastian De Bono. Proselica Study Update: Comparison of Two Doses of Cabazitaxel (Cbz) + Prednisone (P) in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with a Docetaxel (D)-Containing Regimen. Abstract #112489. Poster #TPS5099^. ASCO (American Society of Clinical Oncology), 31^st May – 4^th June 2013.

 

33. Daniel J. George, Tracy McGowan, Gedske Daugaard, Thomas W. Flaig, Lajos Géczi, Sebastien J. Hotte, Paul N.  Mainwaring, Fred Saad, Matthew R. Smith, Ciro de Souza, Cora N  Sternberg, Miah Hiang Tay, José Manuel Tello Garrido,  Anil Londhe, Vahid Naini, Mary Beth Todd, Arturo Molina. Interim Safety Results of a Global Early Access Protocol (EAP) of Abiraterone Acetate (AA) in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressing after Taxane-Based Chemotherapy. Abstract #113212. ASCO (American Society of Clinical Oncology), 31^st May – 4^th June 2013.

 

34. Paul de Souza, Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Neal D. Shore, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D Hainsworth, Thomas M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Long Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Study COU-AA-302 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy. ASCO (American Society for Clinical Oncology) Annual Meeting. 31^st May – 4^th June 2013. Chicago IL. USA.

 

35. Fred Saad, Neal D Shore, Hendrik Van Poppel, Dana Rathkopf, Matthew R Smith, Johann S de Bono, Christopher Logothetis, Paul de Souza, Karim Fizazi, Peter F A Mulders, Paul Mainwaring, John D Hainswaroth, Tomasz M Beer, Scott North, Yves Fradet, Tom Griffin, Thian Kheoh, Eric J Small, Howard I Scher, Arturo Molina, Charles J Ryan. Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy – Interim Analysis of the COU-AA-302 Phase 3 Trial. (AUA – American Urological Association), San Diego, CA; May 4-8, 2013.

 

36. Neal Shore, Ethan Basch, Charles J. Ryan, Peter Mulders, Thian Kheoh, Karim Fizazi, Christopher J. Logothetis, Dana Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles Cleeland. The Impact Of Abiraterone Acetate Therapy on Patient-Reported Pain and Functional Status in Chemotherapy Naїve Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer – Results From An Updated Analysis. Poster #784. AUA (American Urological Association) Annual Meeting, 4^th -8^th May 2013. San Diego. CA. USA.

 

37. Hendrik Van Poppel, Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth. Thomasz M. Beer, Scott North, Yves Fradet, Tom Griffin, Yun C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan on behalf of the COU-AA-302 Investigators. Updated Interim Analysis: Results of Randomized Phase 3 Study COU-AA-302 of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy. Poster.  European Association of Urology Congress. 15^th – 19^th March 2013. Milan, Italy.

 

38. Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Long Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy (COU-AA-302). Poster. ASCO Genitourinary Cancers Symposium. 14^th – 16^th February 2013. Florida.

 

39. Fred Saad. Lead author on behalf of COU-AA-302 Investigators. Encore Presentations: Abiraterone Study 302 Interim Analysis, OS 43%. QUA (Quebec Urological Association). 9^th – 11^th November 2012. Quebec.

 

40. Paul de Souza. Lead author on behalf of COU-AA-302 Investigators. Encore Presentations: Abiraterone Study 302 Interim Analysis, OS 43%. COSA (Clinical Oncological Society of Australia). 13^th – 15^th November 2012. Brisbane. Australia.

 

41. Mainwaring, O.B.Goodman, Jr, K.N. Chi, A.Molina, C.Logothetis, R.J. Jones, J.N. Staffurth, S. North, N. Vogelzang, F. Saad, S. Harland, J. Li, T. Kheoh, C.M. Haqq, H.I Scher, K. Fizazi. A Phase 3 Study COU-AA-301of Abiraterone Acetate (AA) Plus Prednisone (P) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): an Exploratory Analysis of Prior Docetaxel (D) Treatment and  Survival Benefit.  COSA 13^th -15^th  November 2012. Brisbane, Australia.

 

42. Ethan Basch, Charles J. Ryan, Thian Kheoh, Karim Fizazi, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles Cleeland, Paul Mainwaring. The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naїve Patients With Progressive, Metastatic Castration-Resistant Prostate Cancer (mCRPC). ESMO 2012 (Vienna, September 28 – October 2).

 

43. Joachim von Pawel, Vera Gorgounova, Martin Reck, Dariusz M. Kowalski, Aurore Allard. Mustapha Chadjaa, Augustin Rey Jaafar Bennouna Francesco Grossi on behalf of the DISRUPT Investigators. DISRUPT: A Randomized Phase 2 Trial of OMBRABULIN (AVE8062) Combined With a Taxane-Platinum Regimen in the First-Line Treatment of Metastatic Non-Small Lung Cancer (NSCLC). Abstract – ESMO Vienna 28 Sept. – 2 Oct. 2012

 

44. Fred Saad. Lead Author on behalf of the COU-AA-302 Investigators. Encore Presentations: Abiraterone Study 302 Interim Analysis, OS 43%. QUA (Quebec Urological Association) Congress. Saint Paulin, Quebec. 14^th 16^th September 2012

 

45. Oudard, L. Sengelov, P. Mainwaring, A. Thiery-Vuillemin, C. Theodore, E. Kulikov, J. Yachnin, I. Kocak, V. Kataja, M. Luukkaa, A Nosov, M. Hjelm-Erkisson, J. Bubis, L. Shen, M-L. Risse, O. Sartor. FIRSTANA First-Line Use of Cabazitaxel in Chemotherapy-naїve Patients With Metastatic Castration-Resistant Prostate Cancer: A Three-Arm Study in Comparison With Docetaxel. Poster, ASCO 1-5 June 2012

 

46. Oscar B. Goodman, Kim N. Chi, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholoas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jinhui Li, Thian Kheoh, Chritopher M. Haqq, Howard I. Scher, Karim Fizazi. Exploratory Analysis of Survival Benefit and Prior Docetaxel Treatment in COU-AA-301, A Phase 3 Study of Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

 

47. Paul Mainwaring, Carmelo Bengala, Antoinette R. Tan, REgigiusz Kaleta, M. Brent McHenry, Ioannis Lainas, Pamela L. Clemens, Pierfranco Conte. A Phase 1 Study of Ixabepilone and Lapatinib in Patients With Her2-Positive, Pretreated Metastatic Breast Cancer.

 

48. J. Ryan, M.R. Smith, J.S. de Bono, A. Molina, C. Logothetis, P. De Souza, K. Fizazi, P. Mainwaring, J.R. Piulats, S. Ng, J. Carles, P.F.A. Mulders, T. Kheoh, T. Griffin, E.J. Small, H. Scher, D. Rathkopf, on behalf of the COU-AA-302 investigators. Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase 3 Study of Abiraterone Acetate (AA) in Chemotherapy-Naїve Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRC). Abstract ASCO Annual Meeting, Chicago, June 1-5 2012.

 

49. Mario Eisenberger, Anne-Claire Hardy-Bessard, Loїc Mourey, Mainwaring, Daniel Ford, Jeremy Shapiro, Joan Carles Galceran, Siobhan Ng, Thierry Gil, Boris Alekseev, Sergey Ivanov, Thomas Facchini, Eric Legouffe, Olg Apolikhin, Hardev Pandha, Aart Beeker, Oleg Karaykin, Wendy Zhang, Mustapha Chadjaa, Johann S de Bono. Comparison of Two Doses of Cabazitaxel Plus Prednisone in Patients with Metastatic Castration-Resistant (mCRPC) Previously Treated With Docetaxel (D)-Containing Regimen. PROSELICA Trial. Abstract submitted to ASCO Annual Meeting. June 1-5 2012

 

 

 

50. Kim N. Chi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jnr.  Exploratory analysis of Survival Benefit and Prior Docetaxel (D) Treatment in COU-hui Li, Thian Kheoh, Christopher M. Haqq, Karim Fizazi. Exploratory Analysis of Survival Benefits and Prior Docetaxel Treatment in COU-AA-301, A Phase 3 Study of Abiraterone Acetate Plus Low-Dose Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #95325. Submitted to ASCO Annual Meeting. 1-5 June 2012

 

51. Robert Motzer, Camillo Porta, Georg A. Bjarnason, Cezary Szczylik, Sun Young Rha, Emilio Esteban, Ugo De Giorgi, Mary McKenzie, Paul Mainwaring, Scott North, Roberto Sabbatini, Istvan Bodrogi, Fairooz Kabbinavar, Giacomo Carteni, Cora N. Sternberg, Nicholoas Vogelzang, Michael Shi, Gladys Urbanowitz, Bernard Escudier. Phase III Trial of Dovitinib (TK1258) versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-Angiogenic (VEGF-Targeted and mTOR Inhibitor) Therapies. Abstract #96688 submitted to ASCO Annual Meeting. 1-5June 2012

 

52. Mainwaring (co-author). Interim Analysis Results of COU-AA-302, A Randomised, Phase III Study of Abiraterone Acetate in Chemotherapy Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #95300 submitted to ASCO Annual Meeting. June 1-5 2012.

 

53. Mainwaring, (co-author). First-Line Use of Cabazitaxel in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Three-Arm Study in Comparison with Docetaxel. Abstract #96516 submitted to ASCO Annual Meeting June 1-5 2012.

 

54. Kim N. Chi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jnr. Exploratory Analysis of Survival Benefit and Prior Docetaxel (D) Treatment in COU-AA-301. A Phase 3 Study of Abiraterone Acetate Plus Low-Dose Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC).Citation: J. Clin Oncol 30, 2012 (suppl. 5; abstr 15) ASCO GU. San Francisco CA Feb. 2-4 2012.

 

55. Ethan Basch, Johann S. de Bono, Howard I. Scher, Arturo Molina, Cora N. Sternberg, Karim Fizazi, Scott A. North, Kim N. Chi, Robert J. Jones, Oscar B. Goodman, Paul N. Mainwaring, Amanda Farr, Margaret Rothman, Yanni Hao, Cameron S. Liu, Thian Kheoh, Chris M. Haqq, Eleni Efstathiou, Christopher Logothetis. Pain Control and Delay in Time to Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate: Long-Term Follow-Up. Citation: J. Clin. Oncol 30, 2012 (suppl 5; abstr 183) ASCO GU Poster. San Francisco CA Feb. 2-4 2012.

 

56. E. Gore, C. Porta, S. Bracarda, L. Crino, R. Hawkins, G. Bjarnason, S. Oudard, S. H. Lee, T. M. Kim, J. Yuan, K. Fly, C. Szczylik. Updated Safety and Efficacy Results for Sunitinib from a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma. ECCO/ESMO Sept. 2011

 

57. Cora N. Sternberg, Howard I. Scher, Arturo Molina, Scott North, Paul Mainwaring, Yanni Hao, Dennis Gagnon, Thian Kheoh, Chris M. Haqq, Johann S. de Bono. Fatigue Improvement/Reduction With Abiraterone In Patients With Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: Results From the COU-AA-301 Phase 3 Study. Poster Presentation. ECCO/ESMO Sept. 2011

 

58. N. Sternberg, H.I. Scher, A. Molina, S. North, P. Mainwaring, Y. Hao, D. Gagnon, C.M. Haqq, J.S. de Bono. Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-Docetaxel: Results from the COU-AA-301 Phase 3 Study. ECCO/ESMO Sept. 2011.

 

 

 

59. Christopher J. Logothetis, Ethen M. Basch, Arturo Molina, Karim Fizazi, Scott A. North, Kim N. Chi, Robert J. Jones, Oscar B. Goodman, Paul N. Mainwaring, Cora N. Sternberg, Eleni Efstathiou, Dennis D. Gagnon, Margaret Rothman, Yanni Hao, Cameron S. Liu,  Thian S.  Kheoh,  Effect of Abiraterone Acetate on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: Results of the COU-AA-301 Study.  Presented as an Oral Presentation at ASCO 2011 Annual Meeting (June 3-7 Chicago IL). Abstract 4520. Submitted to Journal of Clinical Oncology Feb. 20 2012 C.N. Stemberg, H.I. Scher, A. Molina, S. North, Mainwaring, Y. Hao, D. Gagnon, T. Kheoh, C.M. Haqq, J.S. de Bono. Fatigue Improvement/Reduction with Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-Docetaxel: Results from the COU-AA-301 Phase 3 Study. April 18 2011.

 

60. N. Stemberg, H.I. Scher, A. Molina, S. North, P. Mainwaring, Y. Hao, D. Gagnon, T. Kheoh, C.M. Haqq, J.S. de Bono. Fatigue Improvement/Reduction with Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-Docetaxel: Results from the COU-AA-301 Phase 3 Study. April 18 2011.

 

61. C. Mita, R.S. Heist, O. Aren, P. Mainwaring, L. Bazhenova, S.M. Gadgeel, R.H. Blum, J. Polikoff, J. Biswas, M.A. Spear. Phase II Study of Docetaxel With or Without Plinabulin (NPI-2358) in Patients with Non-Small Cell Lung Cancer (NSCLC). ASCO 2010 Annual Meeting. Abstract #7592. Citation:J Clin Oncol 28:15s, 2010 (suppl; abstr 7592). Category: Lung Cancer – Metastatic-Metastatic. Background: Plinabulin (NPI-2358) is a Vascular Disrupting Agent 9VDA That Acts on the Cytoskeleton to Destabilize Tumour Vascular Endothelial Cell Cohesion With Addition Cytotoxic Activity, Leading to Selective Tumour Vascular Disruption and Necrosis.

 

62. Mainwaring (added as a co-author). A Multicentre, Open-Label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects with Primary or Secondary Hepatic Tumour Burden. Abstract #51187. American Society of Clinical Oncology (ASCO). June 4-8 2010

 

63. Mainwaring (added as a co-author). Randomized Phase 3 Study of Panitumumab (pmab) with FOLFIRI vs FOLFIRI Alone as 2^nd‑ Line Treatment (Tx) in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Analysis by Tumour Epidermal Growth Factor Receptor (EGFR) Staining. Abstract #53127. American Society of Clinical Oncology (ASCO). June 4-8 2010

 

64. Mainwaring (added as a co-author). Phase 2 Study of Docetaxel +/- Plinabulin (NPI-2358) in Patients with Non Small Cell Lung Cancer (NSCLC). Abstract #48380. American Society of Clinical Oncology (ASCO). June 4-8 2010.

 

65. Twelves, D. Loesch, J.L. Blum, L.T. Vahdat, K. Petrakova, P.J. Chollet, C.E. Akerele, S. Seegobin, J. Wanders, J. Cortes, on behalf of the Study 305 investigators.. A Phase II Study (EMBRACE) of Eribulin Mesylate versus Treatment of Physician’s Choice in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane. Abstract # CRA1004^. Sub-Category: Metastatic Breast Cancer. Category: Breast Cancer –Metastatic Breast Cancer. Citation: J Clin Oncol 28:18s,2010 (suppl; abstr CRA1004^). American Society of Clinical Oncology. (ASCO 2010) June 4-8 2010.

 

66. N Mainwaring, J. Lickliter, M.P. Brown, M. Millward, D.J. Chaplin, Z. Goldberg. A Multi-Centre, Open-Label, Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden. ASCO 2010 Annual Meeting. Abstract #TPS164. Citation: j Clin Oncol 28:15s, 2010 (suppl; abstr TPS164). Category: Development Therapeutics – Clinical Pharmacology and Immunotherapy – Phase 1 Studies. Background: Combretastatin A1 diphosphate (CAIP, Oxi4503) is a Novel Vascular Disrupting Agent (VDA) that is a Reversible Tubulin-Binding Agent with Direct Cytotoxic Activity when Bioactivated to its Reactive Orthoquinone Metabolite.

 

 

 

67. Peeters, A. Cervantes-Ruiperez, A.Strickland, T.Ciuleanu, P.N. Mainwaring, V.I. Tzekova, A.Santoro, C.S.Johnson, A.Zhang, J.L.Gansert. Randomized Phase III Study of Panitumumab (pmab) with FOLFIRI versus FOLFIRI Alone as 2nd Line Treatment (tx) in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Analysis by Tumor Epidermal Growth Factor Receptor (EGFR) Staining. ASCO 2010 Annual Meeting. Abstract #3565^. Citation: J Clin Oncol 28:15s, 2010 (suppl; abstr 3565^. Category: Gastrointestinal (Colorectal) Cancer – Colorectal Cancer. Background: Pmab, A Fully Human, Anti-EGFR Monoclonal Antibody, plus FOLFIRI vs FOLFIRI was Evaluated as 2^nd-line Tx for mCRC by Tumour KRAS Status; Efficacy Analyses by EGFR Staining Were Also Performed. Methods: Patients who received 1 prior chemotherapy

 

68. Peter Kaufman, Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Bob Sikorski, dusan Kotasek.. Phase 1b Study of Motesanib Diphosphate Plus Paclitaxel or Docetaxel for Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer: Interim Results. ESMO/ECCO 2009

 

69. Lee, HC Chung, P. Mainwaring, MH Toh, C. Ng, WC Chang, P. Kwong, R. Li, V. Sriuranpong, TC. Keong, SP Lowenthal.. An Asian Subpopulation Analysis of the Safety and Efficacy of Sunitinib in Metastatic Renal Cell Carcinoma. ECCO/ESMO 2009

 

70. Michael Millward, Paul Mainwaring, Matthew A. Spear, Monica Mita, Kristine Federico, G. Kenneth-Lloyd, Gillian Cropp, Alain Mita. The Novel Vascular Disrupting Agent (VDA) NPI-2358 Combined With Docetaxel in Patients with NSCLC. IASLC. March 2009 and ASCO 2010.

 

71. Peter Kaufman, Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Bob Sikorski, dusan Kotasek.. Phase 1b Study of Motesanib Diphosphate Plus Paclitaxel or Docetaxel for Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer: Interim Results. SABCS 2008 and ESMO/ECCO 2009

 

72. Amanda Townsend, Michael Millward, Timothy Price, Paul Mainwaring, Andrew Spencer, Angie Longenecker, Michael A. Palladino, G. Kenneth Lloyd, Matthew A. Spear, Peeter Padrik. Clinical Trial of NPI-0052 in Advanced Malignancies Including Lymphoma and Leukemia (Advanced Malignancies Arm). Abstract American Society of Clinical Oncology (ASCO) June 2009.

 

73. Ahmad A. Tarhini, Michael Millward, Paul Mainwaring, Richard Kefford, Ted Logan, Anna Pavlick, Steven J Kathman,  Kevin H. Laubscher, Mohammed M. Dar, and John M. Kirkwood. A Phase II, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma.

 

74. Mark McKeage, Michael Jameson, David Gibbs, Mark Rosental, Paul Mainwaring, Joachim von Pawl (for AS1404-201 Study Investigators). Abstract NZSO June 2008

 

75. Mainwaring.. A Phase 1a Safety and Pharmacokinetic Study of Oral NV-196 in Patients With Solid Tumours. ASCO June 2008

 

76. Amanda Townsend, Peeter Padrick, Paul Mainwaring, Timothy Price, Laurence Catley, Angie Longenecker, Michael A. Palladino, G. Kenneth Lloyd, Matthew A Speark, Michael Millward. Phase 1 Clinical Trial of the 2^nd Generation Proteasome Inhibitor NPI-0052 in Patients With Advanced Malignancies With a CLLRP2D Cohort. NCI-EORTC May 2008. ASCO June 2009

 

77. Richard de Boer, Peter Kaufman, Shane White, Paul Mainwaring, Bogda Koczwara,Yining Ye, Yu-Nien Sun, Mandy Parson, Ada Braun, and Dusan Kotasek.. Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer With Motesanib Diphosphate Plus Paclitaxel or Docetaxel: Results From a Phase 1b Study. EBCC 2008 A 582

 

78. P. Ackland, S. Clarke, R. Perez-Carrión, S. Chiara, J. Gapski, P. Mainwaring, B. Langer, S. Young, A. Sobrero and colleagues. Updated Efficacy Data From Aviri, A Large Phase I Trial of First-Line Bevacizumab Plus Folfiri In Patients With Metastatic Colorectal Cancer. ASCO GI 2008 A463

 

79. Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Mandy Parson, Ada Braun and Dusan Kotasek.. Safety and Pharmacokinetics of Motesanib Diphosphate (AMG 706) With Paclitaxel or Docetaxel for the Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer. SABCS 2007

 

80. Martin E. Gore, Cezary Szczylik, Camillo Porta, George Bjarnason, Stephen Oudard, Subramanian Hariharan, Se-Hoon Lee, John Haanen, Dniel Castellano, Eduard Vrdoljak, Patrick Schoffski, Paul Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald Bukowski. Safety and Efficacy of Suninitib with Subpopulation Analysis in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma. 14^th European Cancer Conference, September 23-27, 2007. Barcelona, Spain.

 

81. Martin E. Gore, Cezary Szczylik, Camillo Porta, George Bjarnason, Stephen Oudard, Subramanian Hariharan, Se-Hoon Lee, John Haanen, Dniel Castellano, Eduard Vrdoljak, Patrick Schoffski, Paul Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald Bukowski. Safety and Efficacy of Suninitib with Subpopulation Analysis in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma. 43^rd Annual Meeting of the American Society of Clinical Oncology (ASCO)  June 1-5, 2007, Chicago, IL

 

82. Sobrero, S. Ackland, S. Clarke, R. Perez-Carrión, S. Chiara, J. Gapski, Mainwaring, M. Balcewicz, B. Langer, S. Young. Final Data From A Large Phase IV Trial of First-Line Bevacizumab Plus Classic or Modified FOLFIRI in Metastatic Colorectal Cancer (CRC). Proc Ann Am Meet Soc Clin Oncol 2007

 

83. N Pavlakis, M Boyer, M Millward, Mainwaring, K Pittman, C Lewis, J Shapiro, R Abraham, F Abell, C Underhill, K Horwood, G Hawson, B.Creese and E.Wilson. Multi-Centre Randomised Phase II Trial of PI-88, a Novel Heparanase Inhibitor, With Weekly Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). World Lung Cancer Conference 2007

 

84. N. Mainwaring, Dr C. Shannon. A11068 PASCO 2007. A Phase II Study of Dose-Dense Chemotherapy {Doxorubicin (A), Cyclophosphamide (C), Paclitaxel (T), Gemcitabine (G)} Supported by Pegfilgrastim (P) and Darbepoetin-alfa (D) for Patients With High-Risk Early Stage Breast Cancer (ICANDO)

 

85. M. Kirkwood, R. Kefford, T. Logan, P. N. Mainwaring, M. Millward, A. C. Pavlick, M. M. Dar, S. Kathman, K. Laubscher, W. Bell. Phase II Trial of Iboctadekin (rhIL-18) on a Daily X 5 Schedule in Metastatic Melanoma (MM). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 10043

 

86. Sizer, A. Makris, C. Barone, P. Mainwaring, P. Eggleton. QoL and Resource Use Analysis of Tegafur-Uracil/LV or 5-FU/LV in First-Line Metastatic Colorectal Cancer (mCRC): Final Results of a Multi-Center Phase II Study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3631

 

87. Pluzanska, P. Mainwaring, J. Cassidy, B. Utracka-Hutka, J. Zalucki, R. Glynne-Jones, P. Koralewski, J. Bridgewater, H. Wasan, D. Cunningham. Final Results of A Randomized Phase III Study Evaluating the Addition of Oxaliplatin First-Line to 5-FU Followed by Irinotecan at Progression in Advanced Colorectal Cancer (LIFE study). Proc Annu Meet Am Soc Clin Oncol 2005 A: 3517

 

88. Vukelja, J. O’Shaughnessy, S. Campos, L. Vahdat, J. Blum, D. Yardley, P. Mainwaring, F. Senecal, R. Benner, L. Denis, E. Perez. Activity of Oral Irinotecan (IRI) in Metastatic Breast Cancer (MBC) Patients After Prior Anthracycline, Taxane and Capecitabine: Phase 2 Study Results. Proc Annu Meet Am Soc Clin Oncol 2005 A562

 

89. Prue, T. Rosetti, S. Fitzpatrick, R. Wilkinson, K. Radford, P. Swindle, P. Mainwaring, D. N. Hart. A Phase I Clinical Trial of a BDCA-1+ Blood Dendritic Cell Preparation Loaded With Control and Tumour-Associated Antigens, for Immune Therapy of Metastatic Refractory Prostate Cancer.  Proc Annu Meet Am Soc Clin Oncol 2005 A2599

 

90. Barone C, Sizer B, Mainwaring PN, Steger G,et al. Randomized Study of Oral UFT (Uracil/Ftorafur) plus Leucovorin (LV) or Parenteral 5-FU/LV in Patients With Metastatic Colorectal Cancer. Fourth International Conference on Colorectal Cancer, Barcelona, A33, 2002

 

91. G. Mikhaeel, P. Mainwaring, T. Nunan, A.T. Timothy. Prognostic Value of Interim and Post-Treatment FDG-PET Scanning in Hodgkin Lymphoma. Guy’s & St. Thomas’ Cancer Centre & Clinical PET Centre, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK. VIII International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2002.

 

92. Cassidy, D. Cunningham, B. Utracka-Hutka, J. Zaluski, R. Glynne-Jones, P. Mainwaring, P. Koralewski, J. Carmichael, L. Mounedji-Boudiaf, A. Pluzanska; Aberdeen Royal Infirmary, Aberdeen, UK; Royal Marsden Hospital, London, UK; Centrum Onkologii Wybrzeze, Gliwice, Poland; Wielkolpolskie Centrum Onkologii, Poznan, Poland; Mount Vernon Hospital, London, UK; St Thomas Hospital, London, UK; Oddzial Chemioterapii Szpital, Krakow, Poland; Nottingham City Hospital, Nottingham, UK; Sanofi-Synthelabo, Paris, France; Szpital Akademii Medycznej, Lodz, Poland. Oxaliplatin (Oxa)/5-FU/LV in First-Line Metastatic Colorectal Cancer Followed by Irinotecan: Interim Results of the Life Study., Proc Annu Am Meet Soc Clin Oncol, 21, A 1064

 

93. Paul N Mainwaring, Eric Van Cutsem, Jean-Luc Van Laethem, David Propper, Christopher Twelves, John Bridgewater, Bruno Audhuy, James Carmichael, Cornelis Punt, Jim Cassidy, Nicholas Stuart, Miroslav Ravic, St Thomas Hospital, London, UK; University Hospital Gasthuisberg, Leuven, Belgium; Erasme University Hospital, Brussels, Belgium; St Bartholomews Hospital, London, UK; Western Infirmary, Glasgow, UK; University College Hospital, London, UK; Hopital Pasteur, Colmar, France; City Hospital, Nottingham, UK; University Medical Centre, Nymegen, Netherlands; Institute of Medical Science, Aberdeen, UK; Ysbyty Gwynedd Hospital, Bangor, UK; Eisai Ltd, London, UK. A Multi-Centre Randomised Phase II Study of E7070 in Patients With Colorectal Cancer Who Have Failed 5-Fluorouracil-Based Chemotherapy. Proc Annu Am Meet Soc Clin Oncol 20, A611

 

94. Seynaeve C, Hough RE, Mainwaring PN, Judson I, Verweij J, Lorigan P. Consolidation High Dose Chemotherapy (HDCT) in Adult Patients With Small Round Blue Cell Tumours (SRBCT), Proc Annu Am Meet Soc Clin Oncol 19, A2214, 2000

 

95. Mainwaring PN, Cunningham D, Gregory W, Linch D, Hoskin P, Hancock B, Vaughan, Hudson G. Mitozantrone Should Replace Doxorubicin In Patients Over 60 Years Of Age Receiving A Modification Of The PACEBOM Regimen. Results Of A BNLI Randomised Study Of PAdriaCEBO Vs. PMitCEBO In Patients With High-Grade Lymphoma. Eur Winter Oncol Meet 1999

 

96. Mainwaring PN, Horton C, Powles R, Treleaven J, Role of Autologous Transplantation in Patients with Multiple Myeloma (MM) aged 65 Years and Over. American Society of Haematology A 2731 Blood A 2731 1998

 

97. Mainwaring PN., Ellis, PA., Detre S, Smith IE, Powles TJ, Dowsett M. Comparison Of Alternative Methods To Assess Apoptosis In Breast Cancer Patients. ASCO A1971 1997

 

98. Dowsett M., Detre S., Ormerod M, Mainwaring PN., Ellis PA., Titley J., Smith IE. Apoptotic Cell Sorting and Analysis in Fine Needle Aspirates (FNAs) from Primary Human Breast Carcinomas (Bcs). AACR 1997; 38: 1589

 

99. Mainwaring PN., Ellis PE., Salter J., Anderson E., Howell A., Nicholson RI., Robertson JF., Smith IE., Reed J., Dowsett, M. Immunohistochemical Expression of BCL-2 and BAX is Unaffected by the Pure Antioestrogen ICI 182,780 in Human Breast Cancer. AACR 1997 38: 767

 

100. Mainwaring PN, Salter J, Johnston SD, Ellis PA, Smith IE, Ebbs SR, Dowsett M. Changes in Molecular Phenotype of Human Breast Carcinomas Associated with Tamoxifen Resistance. San Antonio Breast Cancer Symposium 1996 A 1567

 

 

 

101. Gore ME., Mainwaring PN., Macfarlane V., A’Hern R., Osborne R., Harper P., Quigley M., Slevin M., Jones A., Mansi J. Blake P. A Randomised Study of High versus Standard Dose Carboplatin in Patients (pts) With Advanced Epithelial Ovarian Cancer (EOC). NCI/EORTC New Drugs Meeting 1995. ASCO 1996 15; 284 A769

 

102. Mainwaring PN., Atkinson H., Chang J., Moore J., Hancock BW., Guillou PJ., Oskam R., Gore ME. High Differential Response Rate in Patients with Metastatic Malignant Melanoma Treated by Biochemotherapy. NCI/EORTC New Drugs Meeting 1995